1 N-Acetyltransferase phenotype has been determined in 109 control subjects and in 23 patients with bladder cancer.
2 Sixty-two per cent of control, and 39% of patients with bladder cancer were phenotypically slow acetylators. This difference was not significant.
3 N-Acetyltransferase phenotype is unlikely to be a major determinant in the development of bladder cancer in the Turkish population.
Get full access to this article
View all access options for this article.
References
1.
Anthony, H.M. & Thomas, G.M. (1970). Tumors of the urinary bladder: an analysis of the occupation of 1030 patients in Leeds, England. J. Natl. Cancer Inst., 45,879-895
2.
Cartwright, R.A., Rogers, H.J., Barham-Hall, D., Glashan, R.W., Ahmad, R.A., Higgins, E. & Khan, M.A. (1982). Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer . Lancet, ii, 842-846.
3.
Cole, P., Hoover, R. & Friedell, G.H. (1972). Occupation and cancer of the lower urinary tract. Cancer, 29, 1250-1260.
4.
Evans, D.A.P. (1969). An improved and simplified method of detecting the acetylator phenotype. J. Med. Genet., 6, 405-407.
5.
Evans, D.A.P. & White, T.A. (1964). Human acetylation polymorphism. J. Lab. Clin. Med., 63, 394-403.
6.
Evans, D.A.P., Eze, L.C. & Whibley, E.J. (1983). The association of the slow acetylator phenotype with bladder cancer. J. Med. Genet., 20, 330-333.
7.
Evans, D.A.P., Manley, K.A. & McKusick, V.A. (1960). Genetic control of isoniazid metabolism in man. Br. Med. J., ii, 485-491.
8.
Glowinski, I.B., Radtke, H.E. & Weber, W.W. (1978). Genetic variation N-acetylation of carcinogenic arylamines by human and rabbit liver. Mol. Pharmacol., 14, 940-949.
9.
Glowinski, I.B. & Weber, W.W. (1982). Genetic regulation of aromatic amine N-acetylation in bred mice. J. Biol. Chem., 257, 1424-1430.
10.
Huper, W.C., Wiley, F.H. & Wolfe, H.D. (1938). Experimental production of bladder tumors in dogs by administration of beta-naphthylane. J. Ind. Hyg. Toxicol. , 20, 46.
11.
King, H. & Bailar, J.C. (1966). Epidemiology of urinary bladder cancer: a review of selected literature. J. Chronic Dis., 19, 735-772.
12.
Lower, G.M., Nilsson, T., Nelson, C.E., Wolf, H., Gamsky, T.E. & Bryan, G.T. (1979). N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect., 29, 71-79.
Lower, G.M. (1983). Arylamines and bladder cancer causality: application of conceptual and operational criteria. Clin. Pharmacol. Ther. , 34, 129-135.
15.
Miller, M.E. & Cosgriff, J.M. (1983). Acetylator phenotype in human bladder cancer. J. Urol., 130, 65-66.
16.
Mommsen, S., Barfod, N.M. & Aagaard, J. (1985). N-Acetyltransferase phenotypes in urinary bladder carcinogenesis of a low risk population. Carcinogenesis, 6, 199-201.
17.
Olson, W., Miceli, J. & Weber, W.W. (1978). Dose-dependent changes in sulphamethazine kinetics in rapid and slow isoniazid acetylators. Clin. Pharmacol. Ther., 23, 204-211.
18.
Rehn, R. (1895). Blasengescchwultse bei fuchsin-arbeiten. Arch. Klin. Chir., 50, 588.
19.
Varley, H. (1962). Practical Clinical Biochemistry, 3rd edn, p. 634. London: Heinemann.
20.
Wolf, H., Lower, G.M. & Bryan, G.T. (1980). Role of N-acetyltransferase phenotype in human suspectibility to bladder carcinogenic arylamines. Scand. J. Urol. Nephrol., 14, 161-165.
21.
Woodhouse, K.W., Adams, P.C., Clothier, A., Mucklow, J.C. & Rawlins, M.D. (1982). N-Acetylation phenotype in bladder cancer. Human Toxicol., 1, 443-445.
22.
Wynder, E.L. & Goldsmith, R. (1977). The epidemiology of bladder cancer. A second look . Cancer., 40,1246-1268.
